CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina ...
quiverquant

CAMP4 Therapeutics Receives MHRA Authorization to Include UK Sites in Global Phase 1/2 Trial of CMP-002 for SYNGAP1-Related Disorder

CAMP4 Therapeutics gains UK MHRA authorization for CMP-002 trial, expanding its global clinical study on SYNGAP1 disorder.